France Nonalcoholic Steatohepatitis Therapeutics Market (2025-2031) | Companies, Competitive Landscape, Forecast, Value, Industry, Trends, Share, Segmentation, Outlook, Size & Revenue, Growth, Analysis

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 France Country Macro Economic Indicators

3.2 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 France Nonalcoholic Steatohepatitis Therapeutics Market - Industry Life Cycle

3.4 France Nonalcoholic Steatohepatitis Therapeutics Market - Porter's Five Forces

3.5 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume Share, By Drug Type, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of nonalcoholic steatohepatitis (NASH) in France

4.2.2 Growing awareness about the importance of early diagnosis and treatment of NASH

4.2.3 Rising investments in research and development of NASH therapeutics

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for approval of NASH therapeutics

4.3.2 Limited availability of effective treatment options for NASH in the market

6.1 France Nonalcoholic Steatohepatitis Therapeutics Market, By Drug Type

6.1.1 Overview and Analysis

6.1.2 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Drug Type, 2021- 2031F

6.1.3 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Obeticholic Acid (OCA), 2021- 2031F

6.1.4 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Aramchol (Arachidyl Amido Cholanoic Acid), 2021- 2031F

6.1.5 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Saroglitazar, 2021- 2031F

6.1.6 France Nonalcoholic Steatohepatitis Therapeutics Market Revenues & Volume, By Elafibranor, 2021- 2031F

7.1 France Nonalcoholic Steatohepatitis Therapeutics Market Export to Major Countries

7.2 France Nonalcoholic Steatohepatitis Therapeutics Market Imports from Major Countries

8.1 Number of clinical trials for NASH therapeutics in France

8.2 Adoption rate of newly approved NASH therapeutics

8.3 Patient adherence to NASH treatment regimens

8.4 Level of investment in NASH research and development

8.5 Percentage of NASH cases diagnosed at an early stage

9.1 France Nonalcoholic Steatohepatitis Therapeutics Market Opportunity Assessment, By Drug Type, 2021 & 2031F

10.1 France Nonalcoholic Steatohepatitis Therapeutics Market Revenue Share, By Companies, 2024

10.2 France Nonalcoholic Steatohepatitis Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters